Drug Trial Radar · NCT06676410
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Code PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Galilee CBR
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. At V0 (W0, D0) all participants will start the antiretroviral treatment described above. From V0 (W0, D0) to V6 (W12, D84) participants randomized to Codivir® will receive Codivir® as complementary therapy to the above antiretrovirals on alternate days (every other day). At V6 (W12, D84) treatment with Codivir® will end. At V7 (W24, D168) participation in the study will end. Viral load will be monitored during the study. In case of failure, participation in the study will be discontinued and the participant will be referred to receive the best treatment available for their case.
Conditions
- HIV
- HIV Infection
Interventions
ICFOther
Application of Informed Consent Form.
Eligibility AssessmentBehavioral
Assessment of inclusion, exclusion and discontinuation criteria.
Demographic dataOther
Collection of demographic data.
Weight, height and BMIDiagnostic test
Weight and height measurement and body mass index calculation.
Vital SignsOther
HR, BP and FR and T°, in addition to oximetry.
Medical evaluationDiagnostic test
Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
Safety examDiagnostic test
Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
Pregnancy testDiagnostic test
β-HCG in urine in non-sterile women
SerologyDiagnostic test
HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
RandomizationOther
Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
Apoptosis markersDiagnostic test
Caspases and Annexin V.
Cell activation markersDiagnostic test
PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
Inflammation markersDiagnostic test
ultrasensitive CRP, D-dimer.
Proviral DNA:Diagnostic test
Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
HIV-specific antibodiesDiagnostic test
Anti-HIV-1 specific antibody titers in plasma.
HIV viral load (RNA)Diagnostic test
Performed on plasma.
Codivir® TrainingBehavioral
The participant is trained to self-inject Codivir®
Dispensing Codivir®Drug
the participant receives Codivir®
Codivir® AccountingOther
The Codivir® used since the last visit is accounted for
Concomitant medicationOther
Record of concomitant medications used.
Adverse eventsOther
Collection and recording of adverse events.
AntiretroviralsDrug
Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination. * Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro. * Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS. * Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS). * Single solid formulation (in 1 tablet) 1x/day with: * Tenofovir (TDF) 300 mg * Lamivudine (3TC) 300 mg * Darunavir (DRV) 800 mg, 1x/day * Ritonavir (RTV) 100 mg, 1x/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: • Estimated viral reservoir size by total blood proviral DNA.Time frame: 12 weeks
- Variation between V-2 (baseline) and V6 (W12) in relation to the following parameter: CD4+ blood countTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RDSS Research Center
São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.